Skip to Main Content

Expanding the Use of Commercial IRBs for Industry-Sponsored Clinical Trials

On January 19, 2024, the Vice Chancellor for Research & Creative Activities (ORCA) Roger Wakimoto and Senior Director for the Office of Human Research Protection Kristin Rochford, jointly announced that effective January 25, 2024, all new FDA-regulated, Industry-sponsored, multi-site research conducted at UCLA will require to use a single IRB.

Accordingly, investigators will need to identify an external IRB that will serve as Reviewing IRB for these research studies and required to submit a request to cede review to an external IRB (PDF) in Bruin IRB.

Department chairs are encouraged to share this information to principal investigators. Impacted investigators should contact the IRB reliance team or contact Rebecca Flores Stellat, Reliance and Regulatory Management Assistant Director, to arrange for assistance.

Please see the BruinPost or visit the IRB Reliance page of the OHRPP website for more details.